Optimind Pharma Corp.
OMND
CNSX
| 05/31/2025 | 02/28/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4.96% | 25.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.96% | 25.39% | |||
| Cost of Revenue | -17.58% | 15.19% | |||
| Gross Profit | 18.54% | 32.46% | |||
| SG&A Expenses | -44.41% | 85.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -38.23% | 63.22% | |||
| Operating Income | 106.54% | -212.24% | |||
| Income Before Tax | 98.93% | -183.33% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 98.93% | -183.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 98.93% | -183.33% | |||
| EBIT | 106.54% | -212.24% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 100.00% | -100.00% | |||
| Normalized Basic EPS | 100.00% | -- | |||
| EPS Diluted | 100.00% | -100.00% | |||
| Normalized Diluted EPS | 100.00% | -- | |||
| Average Basic Shares Outstanding | -4.72% | 0.10% | |||
| Average Diluted Shares Outstanding | -4.72% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||